BIOMAT Database Logo BIOMAT Database Logo

Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. 1997

B Barlogie, and S Jagannath, and D H Vesole, and S Naucke, and B Cheson, and S Mattox, and D Bracy, and S Salmon, and J Jacobson, and J Crowley, and G Tricot
Division of Hematology/Oncology, University of Arkansas for Medical Sciences, Little Rock 72205, USA.

Virtually no progress has been made during more than 2 decades of clinical trials for multiple myeloma (MM) involving standard therapy (ST). Recent studies suggest that dose intensification requiring hematopoietic stem cell support results in higher complete response (CR) rates and extended disease control. "Total Therapy" (TT) consisting of noncross-resistant induction regimens, followed by a double autotransplant (AT) procedure, was administered to 123 untreated patients with symptomatic MM. Upon hematologic recovery, interferon (IFN) maintenance (3 million units [MU]/m2 subcutaneously thrice weekly) was given until disease recurrence/progression. Results were compared with the outcome of untreated patients receiving ST according to Southwest Oncology Group (SWOG) trials. One hundred sixteen pair mates were selected from both TT and among 1,123 patients to match for the major prognostic features. TT induced CR in 40% of all 123 patients (intent-to-treat). By 12 months, 7% had died, including 4% from treatment-related complications. With a median follow-up of 31 months, median durations of event-free survival (EFS) and overall survival (OS) are 49 and 62+ months, respectively. Abnormalities of chromosomes 11q and 13 were associated with inferior outcome, whereas CR within 6 months after induction was a favorable prognostic feature for both EFS and OS. In comparison to ST, TT induced higher PR rates (85% v 52%, P < .0001) (CR rates not available on SWOG trials) and extended EFS (49 v 22 months, P = .0001) and OS (62+ v 48 months, P = .01). Compared to ST, dose intensification with double AT markedly augments tumor cytoreduction, effecting not only higher CR rates but also significantly extending EFS and OS in previously untreated patients with MM.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009101 Multiple Myeloma A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY. Myeloma, Plasma-Cell,Kahler Disease,Myeloma, Multiple,Myeloma-Multiple,Myelomatosis,Plasma Cell Myeloma,Cell Myeloma, Plasma,Cell Myelomas, Plasma,Disease, Kahler,Multiple Myelomas,Myeloma Multiple,Myeloma, Plasma Cell,Myeloma-Multiples,Myelomas, Multiple,Myelomas, Plasma Cell,Myelomas, Plasma-Cell,Myelomatoses,Plasma Cell Myelomas,Plasma-Cell Myeloma,Plasma-Cell Myelomas
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000380 Agranulocytosis A decrease in the number of GRANULOCYTES; (BASOPHILS; EOSINOPHILS; and NEUTROPHILS). Granulocytopenia,Agranulocytoses,Granulocytopenias
D000971 Antineoplastic Combined Chemotherapy Protocols The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form. Anticancer Drug Combinations,Antineoplastic Agents, Combined,Antineoplastic Chemotherapy Protocols,Antineoplastic Drug Combinations,Cancer Chemotherapy Protocols,Chemotherapy Protocols, Antineoplastic,Drug Combinations, Antineoplastic,Antineoplastic Combined Chemotherapy Regimens,Combined Antineoplastic Agents,Agent, Combined Antineoplastic,Agents, Combined Antineoplastic,Anticancer Drug Combination,Antineoplastic Agent, Combined,Antineoplastic Chemotherapy Protocol,Antineoplastic Drug Combination,Cancer Chemotherapy Protocol,Chemotherapy Protocol, Antineoplastic,Chemotherapy Protocol, Cancer,Chemotherapy Protocols, Cancer,Combinations, Antineoplastic Drug,Combined Antineoplastic Agent,Drug Combination, Anticancer,Drug Combination, Antineoplastic,Drug Combinations, Anticancer,Protocol, Antineoplastic Chemotherapy,Protocol, Cancer Chemotherapy,Protocols, Antineoplastic Chemotherapy,Protocols, Cancer Chemotherapy

Related Publications

B Barlogie, and S Jagannath, and D H Vesole, and S Naucke, and B Cheson, and S Mattox, and D Bracy, and S Salmon, and J Jacobson, and J Crowley, and G Tricot
Standard therapy versus autologous transplantation in multiple myeloma.
February 1997, Hematology/oncology clinics of North America,
B Barlogie, and S Jagannath, and D H Vesole, and S Naucke, and B Cheson, and S Mattox, and D Bracy, and S Salmon, and J Jacobson, and J Crowley, and G Tricot
Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma.
July 2005, Blood,
B Barlogie, and S Jagannath, and D H Vesole, and S Naucke, and B Cheson, and S Mattox, and D Bracy, and S Salmon, and J Jacobson, and J Crowley, and G Tricot
Bortezomib for previously untreated multiple myeloma.
August 2011, Expert review of hematology,
B Barlogie, and S Jagannath, and D H Vesole, and S Naucke, and B Cheson, and S Mattox, and D Bracy, and S Salmon, and J Jacobson, and J Crowley, and G Tricot
Bortezomib for previously untreated multiple myeloma.
November 2011, Expert opinion on pharmacotherapy,
B Barlogie, and S Jagannath, and D H Vesole, and S Naucke, and B Cheson, and S Mattox, and D Bracy, and S Salmon, and J Jacobson, and J Crowley, and G Tricot
Tandem autologous versus autologous/allogeneic transplantation for multiple myeloma: propensity score analysis.
September 2016, Leukemia & lymphoma,
B Barlogie, and S Jagannath, and D H Vesole, and S Naucke, and B Cheson, and S Mattox, and D Bracy, and S Salmon, and J Jacobson, and J Crowley, and G Tricot
[Treatment of untreated multiple myeloma patients ineligible for autologous stem cell transplantation].
October 2014, [Rinsho ketsueki] The Japanese journal of clinical hematology,
B Barlogie, and S Jagannath, and D H Vesole, and S Naucke, and B Cheson, and S Mattox, and D Bracy, and S Salmon, and J Jacobson, and J Crowley, and G Tricot
Autologous bone marrow transplantation therapy for multiple myeloma.
January 1989, European journal of haematology. Supplementum,
B Barlogie, and S Jagannath, and D H Vesole, and S Naucke, and B Cheson, and S Mattox, and D Bracy, and S Salmon, and J Jacobson, and J Crowley, and G Tricot
Autologous transplantation for multiple myeloma.
September 2008, Annals of oncology : official journal of the European Society for Medical Oncology,
B Barlogie, and S Jagannath, and D H Vesole, and S Naucke, and B Cheson, and S Mattox, and D Bracy, and S Salmon, and J Jacobson, and J Crowley, and G Tricot
Bortezomib for the treatment of previously untreated multiple myeloma.
April 2013, Immunotherapy,
B Barlogie, and S Jagannath, and D H Vesole, and S Naucke, and B Cheson, and S Mattox, and D Bracy, and S Salmon, and J Jacobson, and J Crowley, and G Tricot
Intensive combined therapy for previously untreated aggressive myeloma.
March 1992, Blood,
Copied contents to your clipboard!